CRDF Profile
Cardiff Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing innovative cancer treatments. The company, based in San Diego, California, is at the forefront of oncology research with a pipeline of proprietary drug candidates designed to address unmet needs in cancer therapy. Cardiff Oncology's lead candidate is onvansertib, an oral selective Polo-like Kinase 1 (PLK1) inhibitor aimed at targeting and disrupting cancer cell proliferation. Onvansertib is undergoing clinical trials for various indications, including metastatic colorectal cancer and other solid tumors and leukemias.
The company is also advancing CY140, a dual inhibitor targeting PLK1, PLK2, and PLK3. CY140 is currently in Phase 1/2 clinical studies, focusing on its efficacy in treating solid tumors and leukemias. Additionally, Cardiff Oncology is developing TROV-054, which is in a Phase 1b/2 clinical trial for use in combination with FOLFIRI and bevacizumab for treating metastatic colorectal cancer. These trials are designed to evaluate the potential of TROV-054 in enhancing treatment responses and improving patient outcomes.
In another significant development, Cardiff Oncology is progressing with TROV-053, which is in Phase II clinical trials in combination with Zytiga for metastatic castration-resistant prostate cancer. This combination therapy aims to leverage the synergistic effects of TROV-053 and Zytiga to provide a more effective treatment option for patients with advanced prostate cancer.
Founded in 1999 and initially known as Trovagene, Inc., Cardiff Oncology, Inc. rebranded in May 2012 to better reflect its focus on oncology. The company serves pharmaceutical manufacturers and is dedicated to pioneering novel cancer therapies through its cutting-edge research and development efforts. With a robust pipeline and a commitment to advancing cancer treatment, Cardiff Oncology continues to make strides in the fight against cancer, striving to bring new hope to patients worldwide
|
